NeoGenomics (NASDAQ:NEO) Releases FY 2025 Earnings Guidance

NeoGenomics (NASDAQ:NEO) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 0.150-0.190 for the period, compared to the consensus earnings per share estimate of 0.200. The company issued revenue guidance of $735.0 million-$745.0 million, compared to the consensus revenue estimate of $735.0 million.

Analysts Set New Price Targets

A number of research firms recently weighed in on NEO. Needham & Company LLC decreased their price objective on NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday, February 19th. Benchmark downgraded NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Jefferies Financial Group assumed coverage on NeoGenomics in a report on Tuesday, December 10th. They set a “buy” rating and a $22.00 price target for the company. Bank of America cut their price objective on shares of NeoGenomics from $19.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 19th. Finally, The Goldman Sachs Group cut their price objective on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research report on Tuesday, January 28th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, NeoGenomics currently has a consensus rating of “Moderate Buy” and a consensus price target of $19.60.

NeoGenomics Price Performance

NeoGenomics stock opened at $10.15 on Thursday. NeoGenomics has a 52 week low of $8.98 and a 52 week high of $19.11. The company’s 50 day moving average price is $14.06 and its two-hundred day moving average price is $15.11. The company has a quick ratio of 1.91, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. The stock has a market cap of $1.30 billion, a P/E ratio of -16.37 and a beta of 1.23.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, February 18th. The medical research company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The firm had revenue of $172.00 million for the quarter, compared to the consensus estimate of $173.40 million. On average, equities analysts predict that NeoGenomics will post -0.2 earnings per share for the current year.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.